Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Apr 16:17:40.
doi: 10.1186/s12931-016-0356-1.

The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis

Affiliations
Meta-Analysis

The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis

Amber L Martin et al. Respir Res. .

Abstract

Background: This study investigated the relationship between changes in lung function (as measured by forced expiratory volume in one second [FEV1]) and the St. George's Respiratory Questionnaire (SGRQ) and economically significant outcomes of exacerbations and health resource utilization, with an aim to provide insight into whether the effects of COPD treatment on lung function and health status relate to a reduced risk for exacerbations.

Methods: A systematic literature review was conducted in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials of adult COPD patients published in English since 2002 in order to relate mean change in FEV1 and SGRQ total score to exacerbations and hospitalizations. These predictor/outcome pairs were analyzed using sample-size weighted regression analyses, which estimated a regression slope relating the two treatment effects, as well as a confidence interval and a test of statistical significance.

Results: Sixty-seven trials were included in the analysis. Significant relationships were seen between: FEV1 and any exacerbation (time to first exacerbation or patients with at least one exacerbation, p = 0.001); between FEV1 and moderate-to-severe exacerbations (time to first exacerbation, patients with at least one exacerbation, or annualized rate, p = 0.045); between SGRQ score and any exacerbation (time to first exacerbation or patients with at least one exacerbation, p = 0.0002) and between SGRQ score and moderate-to-severe exacerbations (time to first exacerbation or patients with at least one exacerbation, p = 0.0279; annualized rate, p = 0.0024). Relationships between FEV1 or SGRQ score and annualized exacerbation rate for any exacerbation or hospitalized exacerbations were not significant.

Conclusions: The regression analysis demonstrated a significant association between improvements in FEV1 and SGRQ score and lower risk for COPD exacerbations. Even in cases of non-significant relationships, results were in the expected direction with few exceptions. The results of this analysis offer health care providers and payers a broader picture of the relationship between exacerbations and mean change in FEV1 as well as SGRQ score, and will help inform clinical and formulary-making decisions while stimulating new research questions for future prospective studies.

Keywords: COPD; Exacerbations; FEV1; Health resource utilization; Regression analysis; SGRQ.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study Attrition in the Systematic Literature Review
Fig. 2
Fig. 2
Relationship between Mean Change in Trough FEV1 and Relative Risk for Any Exacerbation
Fig. 3
Fig. 3
Relationship between Mean Change in Trough FEV1 and Risk for a Moderate-to-Severe Exacerbation
Fig. 4
Fig. 4
Relationship between Mean Change in SGRQ Total Score and Risk for Any Exacerbation
Fig. 5
Fig. 5
Relationship between Mean Change in SGRQ Total Score and Risk for a Moderate-to-severe Exacerbation
Fig. 6
Fig. 6
Relationship between Mean Change in FEV1 and Risk for Hospitalization
Fig. 7
Fig. 7
Relationship between Mean Change in SGRQ and Risk for Hospitalization

References

    1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523–532. doi: 10.1183/09031936.06.00124605. - DOI - PubMed
    1. Afonso AS, Verhamme KM, Sturkenboom MC, Brusselle GG. COPD in the general population: prevalence, incidence and survival. Respir Med. 2011;105:1872–1884. doi: 10.1016/j.rmed.2011.06.012. - DOI - PubMed
    1. Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007–2010. Respir Res. 2013;14:103. doi: 10.1186/1465-9921-14-103. - DOI - PMC - PubMed
    1. Halpin DM, Tashkin DP. Defining disease modification in chronic obstructive pulmonary disease. COPD. 2009;6:211–225. doi: 10.1080/15412550902918402. - DOI - PMC - PubMed
    1. How Is COPD Treated? [http://www.nhlbi.nih.gov/health/health-topics/topics/copd/treatment]. Accessed 10 Nov 2015.

Publication types

MeSH terms

Substances